Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value Atai Beckley N.V. (NASDAQ:ATAI) is one of the top penny stocks to buy in investors’ stock portfolio.
On May 12, ATAI Beckley (NASDAQ:ATAI) delivered solid first-quarter results and a business update as it continues to develop its pipeline
The company remains on track to proceed with the Phase 3 Pivotal program for BPL-003, a proprietary intranasal formulation of the short-acting psychedelic. The company is also anticipating topline Phase 2 results for VLS-01, an investigational transmucosal (buccal) film containing N,N-Dimethyltryptamine (DMT), in the fourth quarter. It has also posted positive Phase 2a data for EMP-01, its oral medication for the treatment of social anxiety disorder.
According to chief executive officer Srinivas Rao, the $209.9 million in cash as of the end of the first quarter will provide a runway to advance the various clinical programs. Net loss in the first quarter widened to $29.8 million from $26.4 million in the same quarter last year. Strong capital position, pipeline breadth, and clinical catalysts position ATAI Beckley to build sustained clinical and shareholder value.